Concepedia

P. Senico

PS

4

Publications

641

Citations

4

H-Index

2009

Active since

Affiliations

Pfizer (United States)(Current)

Samsung Medical Center

Memorial Sloan Kettering Cancer Center

P. Senico is an author at Pfizer (United States) specializing in oncology, radiation oncology, and medicine.

Top concepts

Publications per year

2009–2017

4

Publications

4

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Thomas E. Hutson, Bernard Escudier, Emilio Esteban et al. · Journal of Clinical Oncology · 2013 · 397 citations · Full text

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

Premal H. Patel, P. Senico, Rafael E. Curiel et al. · Clinical Genitourinary Cancer · 2009 · 167 citations

, , +6

Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial

Thomas E. Hutson, Bernard Escudier, Georg A. Bjarnason et al. · Annals of Oncology · 2012 · 63 citations

, , +7

P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC

Hatim Husain, Renato Martins, Sarah B. Goldberg et al. · Journal of Thoracic Oncology · 2017 · 14 citations

, , +9

Rows per page

1–4 of 4